Colonization with resistant microorganisms in patients transferred from abroad: who needs to be screened?

Antimicrobial Resistance and Infection Control

T. Kaspar³  A. Schweiger²  S. Droz¹  J. Marschall³ 

[1] Institute for Infectious Diseases, University of Bern, Bern, Switzerland

[2] Department of Internal Medicine, University Hospital Basel, Basel, Switzerland

[3] Department of Infectious Diseases and Prevention, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland

关键词: International travel;    Colonization;    Gram–negative bacteria;    Multi-drug resistant organisms;    Screening;   

Others  :  1230977
DOI  :  10.1186/s13756-015-0071-6

 received in 2014-11-16, accepted in 2015-07-07,  发布年份 2015

【 摘 要 】

Background

While multi-drug resistant organisms (MDRO) are a global phenomenon, there are significant regional differences in terms of prevalence. Traveling to countries with a high MDRO prevalence increases the risk of acquiring such an organism. In this study we determined risk factors for MDRO colonization among patients who returned from a healthcare system in a high-prevalence area (so-called transfer patients). Factors predicting colonization could serve as screening criteria to better target those at highest risk.

Methods

This screening study included adult patients who had been exposed to a healthcare system abroad or in a high-prevalence region in Switzerland over the past six months and presented to our 950-bed tertiary care hospital between January 1, 2012 and December 31, 2013, a 24-month period. Laboratory screening tests focused on Gram-negative MDROs and methicillin-resistant Staphylococcus aureus (MRSA).

Results

A total of 235 transfer patients were screened and analyzed, of which 43 (18 %) were positive for an MDRO. Most of them yielded Gram-negative bacteria (42; 98 %), with only a single screening revealing MRSA (2 %); three screenings showed a combination of Gram-negative bacteria and MRSA. For the risk factor analysis we focused on the 42 Gram-negative MDROs. Most of them were ESBL-producing Escherichia coli and Klebsiella pneumoniae while only two were carbapenemase producers. In univariate analysis, factors associated with screening positivity were hospitalization outside of Europe (p < 0.001), surgical procedure in a hospital abroad (p = 0.007), and - on admission to our hospital - active infection (p = 0.002), antibiotic treatment (p = 0.014) and presence of skin lesions (p = 0.001). Only hospitalization outside of Europe (Odds Ratio, OR 3.2 (95 % CI 1.5- 6.8)) and active infection on admission (OR 2.7 (95 % CI 1.07- 6.6)) remained as independent predictors of Gram-negative MDRO colonization.

Conclusion

Our data suggest that a large proportion of patients (i.e., 82 %) transferred to Switzerland from hospitals in high MDRO prevalence areas are unnecessarily screened for MDRO colonization. Basing our screening strategy on certain criteria (such as presence of skin lesions, active infection, antibiotic treatment, history of a surgical procedure abroad and hospitalization outside of Europe) promises to be a better targeted and more cost-effective strategy.

【 授权许可】

   
2015 Kaspar et al.

【 参考文献 】

• [1]Ho J, Tambyah PA, Paterson DL. Multiresistant Gram-negative infections: a global perspective. Curr Opin Infect Dis. 2010; 23(6):546-553.
• [2]Lepelletier D, Andremont A, Grandbastien B. Risk of highly resistant bacteria importation from repatriates and travelers hospitalized in foreign countries: about the French recommendations to limit their spread. J Trav Med. 2011; 18(5):344-351.
• [3]ecdc. Surveillance report, Antimicrobial resistance surveillance in Europe 2012. 2013. http://www. ecdc.europa.eu/en/publications/Publications/antimicrobial-resistance-surveillance-europe-2012.pdf webcite
• [4]Hawser SP, Badal RE, Bouchillon SK, Hoban DJ, Biedenbach DJ, Canton R et al.. Monitoring the global in vitro activity of ertapenem against Escherichia coli from intra-abdominal infections: SMART 2002-2010. Int J Antimicrob Agents. 2013; 41(3):224-228.
• [5]anresis.ch: Meldungen ausgewählter multiresistenter Mikroorganismen in der Schweiz. Bulletin 40/41 Bundesamt für Gesundheit. 2014; 40:642-643.
• [6]Schwaber MJ, Carmeli Y. Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. J Antimicrob Chemother. 2007; 60(5):913-920.
• [7]Lautenbach E, Patel JB, Bilker WB, Edelstein PH, Fishman NO. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin Infect Dis. 2001; 32(8):1162-1171.
• [8]Nemeth J, Ledergerber B, Preiswerk B, Nobile A, Karrer S, Ruef C et al.. Multidrug-resistant bacteria in travellers hospitalized abroad: prevalence, characteristics, and influence on clinical outcome. J Hosp Infect. 2012; 82(4):254-259.
• [9]Sanchini A, Spitoni MG, Monaco M, Raglio A, Grigis A, Petro W et al.. Outbreak of skin and soft tissue infections in a hospital newborn nursery in Italy due to community-acquired meticillin-resistant Staphylococcus aureus USA300 clone. J Hosp Infect. 2013; 83(1):36-40.
• [10]Rettedal S, Lohr IH, Natas O, Giske CG, Sundsfjord A, Oymar K. First outbreak of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae in a Norwegian neonatal intensive care unit; associated with contaminated breast milk and resolved by strict cohorting. APMIS. 2012; 120(8):612-621.
• [11]Kaiser AM, Schultsz C, Kruithof GJ, Debets-Ossenkopp Y, Vandenbroucke-Grauls C. Carriage of resistant microorganisms in repatriates from foreign hospitals to The Netherlands. Clin Microbiol Infect. 2004; 10(11):972-979.
• [12]Rogers BA, Aminzadeh Z, Hayashi Y, Paterson DL. Country-to-country transfer of patients and the risk of multi-resistant bacterial infection. Clin Infect Dis. 2011; 53(1):49-56.
• [13]Johnson AP, Woodford N. Global spread of antibiotic resistance: the example of New Delhi metallo-beta-lactamase (NDM)-mediated carbapenem resistance. Indian J Med Microbiol. 2013; 62(Pt 4):499-513.
• [14]Kuster SP, Hasse B, Huebner V, Bansal V, Zbinden R, Ruef C et al.. Risks factors for infections with extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae at a tertiary care university hospital in Switzerland. Infection. 2010; 38(1):33-40.
• [15]Kommission für Krankenhaushygiene und Infektionsprävention (KRINKO), Ergänzung zu den „Hygienemassnahmen bei Infektionen oder Besiedlung mit multiresistenten gramnegativen Stäbchen“. Epidemiol Bull. 2014; 21:183-184.
• [16]Siegel JD RE, Jackson M, Chiarello L, and the Healthcare Infection Control Practices Advisory Committee. 2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Healthcare Settings 2007. http://www. cdc.gov/ncidod/dhqp/pdf/isolation2007.pdf webcite
• [17]Empfehlung der Kommission für Krankenhaushygiene und Infektionsprävention (KRINKO) beim Robert Koch –Institut (RKI). Hygienemassnahmen bei Infektionen oder Besiedlung mit multiresistenten gramnegativen Stäbchen. Bundesgesundheitsbl. 2012; 55:1311-1354.
• [18]Widmer A RC, Troillet N. Neue Isolationsrichtlinien in den USA für Spitäler und andere Gesundheitseinrichtungen: Bedeutung für die Schweiz. Swissnoso Bulletin 2009;15(1):2-8.
• [19]Tissot F WA, Kuster SP, Zanetti G. Enterobacteriaceae mit Breitspektrum Beta-Laktamasen (ESBL) im Spital: Neue Empfehlung Swissnoso 2014. Swissnoso Bulletin. 2014;18(2):1-8
• [20]Fankhauser C, Zingg W, Francois P, Dharan S, Schrenzel J, Pittet D et al.. Surveillance of extended-spectrum-beta-lactamase-producing Enterobacteriaceae in a Swiss Tertiary Care Hospital. Swiss Med Wkly. 2009; 139(51-52):747-751.
• [21]Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Second Informational Supplement. CLSI document M100-S18. Clinical and Laboratory Standards Institute, Wayne, PA; 2012.
• [22]Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Thyrd Informational Supplement. CLSI document M100-S18. Clinical and Laboratory Standards Institute, Wayne, PA; 2013.
• [23]Seiffert SN, Marschall J, Perreten V, Carattoli A, Furrer H, Endimiani A. Emergence of Klebsiella pneumoniae co-producing NDM-1, OXA-48, CTX-M-15, CMY-16, QnrA and ArmA in Switzerland. Int J Antimicrob Agents. 2014; 44(3):260-262.
• [24]Weisenberg SA, Mediavilla JR, Chen L, Alexander EL, Rhee KY, Kreiswirth BN et al.. Extended spectrum beta-lactamase-producing Enterobacteriaceae in international travelers and non-travelers in New York City. PloS one. 2012; 7(9):e45141.
• [25]Peirano G, Laupland KB, Gregson DB, Pitout JD. Colonization of returning travelers with CTX-M-producing Escherichia coli. J Travel Med. 2011; 18(5):299-303.
• [26]Tangden T, Cars O, Melhus A, Lowdin E. Foreign travel is a major risk factor for colonization with Escherichia coli producing CTX-M-type extended-spectrum beta-lactamases: a prospective study with Swedish volunteers. Antimicrob Agents Chemother. 2010; 54(9):3564-3568.
• [27]Paltansing S, Vlot JA, Kraakman ME, Mesman R, Bruijning ML, Bernards AT et al.. Extended-spectrum beta-lactamase-producing enterobacteriaceae among travelers from the Netherlands. Emerg Infect Dis. 2013; 19(8):1206-1213.
• [28]Harbarth S, Sax H, Uckay I, Fankhauser C, Agostinho A, Christenson JT et al.. A predictive model for identifying surgical patients at risk of methicillin-resistant Staphylococcus aureus carriage on admission. J Am Coll Surg. 2008; 207(5):683-689.
• [29]Pena C, Gudiol C, Tubau F, Saballs M, Pujol M, Dominguez MA et al.. Risk-factors for acquisition of extended-spectrum beta-lactamase-producing Escherichia coli among hospitalised patients. Clin Microbiol Infect. 2006; 12(3):279-284.
• [30]Peleg AY, Hooper DC. Hospital-acquired infections due to gram-negative bacteria. N Engl J Med. 2010; 362(19):1804-1813.
• [31]Safdar N, Maki DG. The commonality of risk factors for nosocomial colonization and infection with antimicrobial-resistant Staphylococcus aureus, enterococcus, gram-negative bacilli, Clostridium difficile, and Candida. Ann Intern Med. 2002; 136(11):834-844.